Skip to main content
. 2021 Dec 9;37(2):273–284. doi: 10.1002/jbmr.4467

Table 5.

Sclerostin Versus CVD Disease Outcomes (LURIC/ALSPAC)

LURIC (N = 2054)
Exposure Outcome Model β (95% CI) p
Sclerostin Friesinger score 1 0.14 (0.09, 0.18) <0.001
Sclerostin Friesinger score 2 0.05 (0.01, 0.09) 0.018
Sclerostin Friesinger score 3 0.03 (−0.02, 0.07) 0.252
HR (95% CI) p
Sclerostin Death from cardiac cause 1 1.21 (1.14, 1.28) <0.001
Sclerostin Death from cardiac cause 2 1.13 (1.03, 1.23) 0.007
Sclerostin Death from cardiac cause 3 1.03 (0.93, 1.15) 0.557
OR (95% CI) p
Sclerostin Coronary artery stenosis a 1 1.47 (1.29, 1.67) <0.001
Sclerostin Coronary artery stenosis a 2 1.16 (1.02, 1.32) 0.026
Sclerostin Coronary artery stenosis a 3 1.09 (0.96, 1.24) 0.189
ALSPAC (N = 3015)
Outcome β (95% CI)
Sclerostin cIMT 1 0.06 (0.03, 0.10) 0.001
Sclerostin cIMT 2 0.02 (−0.02, 0.05) 0.409
Sclerostin cIMT 3 0.01 (−0.02, 0.05) 0.550
Sclerostin Av. distensibility 1 −0.02 (−0.05, 0.02) 0.328
Sclerostin Av. distensibility 2 0.02 (−0.01, 0.06) 0.183
Sclerostin Av. distensibility 3 0.03 (−0.01, 0.07) 0.106

CVD = cardiovascular disease; LURIC = Ludwigshafen Risk and Cardiovascular Health; ALSPAC = Avon Longitudinal Study of Parents and Children; CI = confidence interval; HR = hazard ratio; OR = odds ratio; cIMT = carotid intima media thickness.

Table shows results of linear/logistic/Cox proportional hazards regression analysis. Results are SD change in outcome/odds/HR of outcome per SD increase in sclerostin, 95% CI, and p value. Model 1: unadjusted; model 2: adjusted for age and ethic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation; model 3: model 2 plus LDL and HDL cholesterol, log triglycerides, diabetes, hypertension, estimated glomerular filtration rate, and apolipoprotein A‐I.

a

Based on n = 2023.